Biosketch Rodrigo Dientsmann

Rodrigo Dientsmann
rdienstmann@vhio.net
Current position
Honors and Membership
  • Active member of the European Society of Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO) and the American Association of Cancer Research (AACR)
Academic Qualifications
  • 2001: Degree in Medicine at Universidade Federal do Rio Grande do Sul, Brazil
  • 2005: Board Certified in Medical Oncology, National Cancer Institute, Brazil
  • 2006-2009: Senior Clinical Research Fellow at National Cancer Institute, Brazil
  • 2010-2012: Fellowship at the Molecular Therapeutics Research Unit of VHIO, Spain
  • 2013: Fellowship at the Molecular Pathology Lab of the Massachusetts General Hospital, Boston, USA
  • 2013-2015: Research Scientist of the Computational Oncology Group at Sage Bionetworks, Seattle, USA
  • 2018-2019: MBA at Esade Business School, Barcelona, Spain
Areas of Research
  • Integration of clinical and translational research with genomics for precision cancer therapy
  • Standardized reports of next-generation sequencing tests and molecular tumor board discussions
  • Collaborative research in cancer genomics, computational oncology and real-world data
  • Informatics and digital solutions for lab and clinical decision support systems in precision oncology
Prizes and Scholarships
  • 2007. International Development Education Award
  • 2009. IMPAKT Susan G. Komen for the Cure Award
  • 2012. La Caixa International Program for Cancer Research & Education Grant
Projects
  1. EUCANCan: a federated network of aligned and interoperable infrastructures for the homogeneous analysis, management and sharing of genomic oncology data for Personalized Medicine.
  2. COLOSSUS: Advancing a Precision Medicine Paradigm in metastatic Colorectal Cancer: Systems based patient stratification solutions.
  3. LEGACy: improving gastric cancer outcomes by applying personalized medicine at the three levels of prevention in Europe and Latin America populations based on an “omics integrative epidemiology” conceptual model.
  4. RAD51 Predict: Patient stratification based on DNA repair functionality for cancer precision medicine.
  5. UpSMART Accelerator Management Team – SMART Experimental Cancer Medicine Trials eNABLED.
  6. Cancer Core Europe (CCE) DART: Building Data Rich Clinical Trials.
  7. Cancer Core Europe (CCE) Consortium’s Basket of Baskets (BoB) clinical trial.
  8. American Association for Cancer Research’s (AACR) Genomics Evidence Neoplasia Information Exchange (GENIE) project.
Most relevant scientific publications
  • Dienstmann R, Tamborero D. Genomic testing for targeted oncology drugs: hopes against hype. Ann Oncol. 2021 Jul;32(7):837-838.
  • Villacampa G, Dienstmann R, Bosch F, Abrisqueta P. Combination of novel molecular targeted agent plus R-CHOP-based regimen versus R-CHOP alone in previously untreated diffuse large B-cell lymphoma (DLBCL) patients: a systematic review and meta-analysis. Ann Hematol. 2021 Dec;100(12):2969-2978.
  • Matos I, Villacampa G, Hierro C, Martin-Liberal J, Berché R, Pedrola A, Braña I, Azaro A, Vieito M, Saavedra O, Gardeazabal I, Hernando-Calvo A, Alonso G, Galvao V, Ochoa de Olza M, Ros J, Viaplana C, Muñoz-Couselo E, Elez E, Rodon J, Saura C, Macarulla T, Oaknin A, Carles J, Felip E, Tabernero J, Dienstmann R, Garralda E. Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials. Eur J Cancer. 2021 Sep;155:168-178.
  • Llop-Guevara A, Loibl S, Villacampa G, Vladimirova V, Schneeweiss A, Karn T, Zahm DM, Herencia-Ropero A, Jank P, van Mackelenbergh M, Fasching PA, Marmé F, Stickeler E, Schem C, Dienstmann R, Florian S, Nekljudova V, Balmaña J, Hahnen E, Denkert C, Serra V. Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial. Ann Oncol. 2021 Dec;32(12):1590-1596.
  • Tamborero D, Dienstmann R, Rachid MH, Boekel J, Baird R, Braña I, De Petris L, Yachnin J,Massard C, Opdam FL, Schlenk R, Vernieri C, Garralda E, Masucci M, Villalobos X, Chavarria E; Cancer Core Europe consortium, Calvo F, Fröhling S, Eggermont A, Apolone G, Voest EE, Caldas C, Tabernero J, Ernberg I, Rodon J, Lehtiö J. Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal. Nat Med. 2020;26(7):992-994.
  • Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, Normanno N, Scarpa A, Robson M, Meric-Bernstam F, Wagle N, Stenzinger A, Bonastre J, Bayle A, Michiels S, Bièche I,Rouleau E, Jezdic S, Douillard JY, Reis-Filho JS, Dienstmann R, André F. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020;S0923- 7534(20):39971-3.
  • Wagner AH, Walsh B, Mayfield G, Tamborero D, Sonkin D, Krysiak K, Deu-Pons J, Duren RP, Gao J, McMurry J, Patterson S, Del Vecchio Fitz C, Pitel BA, Sezerman OU, Ellrott K, Warner JL, Rieke DT, Aittokallio T, Cerami E, Ritter DI, Schriml LM, Freimuth RR, Haendel M, Raca G, Madhavan S, Baudis M, Beckmann JS, Dienstmann R, Chakravarty D, Li XS, Mockus S, Elemento O, Schultz N, Lopez- Bigas N, Lawler M, Goecks J, Griffith M, Griffith OL, Margolin AA; Variant Interpretation for Cancer Consortium. A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer. Nat Genet. 2020;52(4):448-457.
  • Dienstmann R, Garralda E, Aguilar S, Sala G, Viaplana C, Ruiz-Pace F, González-Zorelle J, Grazia LoGiacco D, Ogbah Z, Ramos Masdeu L, Mancuso F, Fasani R, Jimenez J, Martinez P, Oaknin A, Saura C, Oliveira M, Balmaña J, Carles J, Macarulla T, Elez E, Alsina M, Braña I, Felip E, Tabernero J, Rodon J, Nuciforo P, Vivancos A. Evolving Landscape of Molecular Prescreening Strategies for Oncology Early Clinical Trials. JCO Precis Oncol. 2020 May 14;4:PO.19.00398.
  • Dienstmann R, Villacampa G, Sveen A, Mason MJ, Niedzwiecki D, Nesbakken A, Moreno V, Warren RS, Lothe RA, Guinney J. Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer. Ann Oncol. 2019 Oct 1;30(10):1622-1629.
  • Dienstmann R, Connor K, Byrne AT; COLOSSUS Consortium. Precision Therapy in RAS Mutant Colorectal Cancer. Gastroenterology 2020;158(4):806-811.
  • Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer. 2017;7(2):79-92.
  • Dienstmann R, Mason MJ, Sinicrope FA, Phipps AI, Tejpar S, Nesbakken A, Danielsen SA, Sveen A, Buchanan DD, Clendenning M, Rosty C, Bot B, Alberts SR, Milburn Jessup J, Lothe RA, Delorenzi M, Newcomb PA, Sargent D, Guinney J. Prediction of overall survival in stage II and III colon cancer beyond the American Joint Commission on Cancer TNM system: a retrospective, pooled biomarker study. Ann Oncol. 2017;28(5):1023-1031.
  • Dienstmann R, Elez E, Argiles G, Matos I, Sanz-Garcia E, Ortiz C, Macarulla T, Capdevila J, Alsina M, Sauri T, Verdaguer H, Vilaro M, Ruiz-Pace F, Viaplana C, Garcia A, Landolfi S, Palmer HG, Nuciforo P, Rodon J, Vivancos A, Tabernero J. Analysis of mutant allele fractions in driver genes in colorectal cancer – biological and clinical insights. Mol Oncol. 2017;11(9):1263-1272.
  • Dienstmann R, Tabernero J. Cancer: A precision approach to tumor treatment. Nature. 2017 Aug 3;548(7665):40-41.
  • Dienstmann R, Jang IS, Bot B, Friend S, Guinney J. Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors. Cancer Discov 2015 Feb; 5(2): 118-23
  • Dienstmann R, Patnaik A, Garcia-Carbonero R, Cervantes A, Benavent M, Roselló S, Tops BB, van der Post RS, Argiles G, Skartved NJ, Hansen UH, Hald R, Pedersen MW, Kragh M, Horak ID, Braun S, Van Cutsem E, Tolcher AW, Tabernero J. Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer. Cancer Discov 2015 Jun; 5(6): 598-609
  • Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, Bot BM, Morris JS, Simon IM, Gerster S, Fessler E, De Sousa E Melo F, Missiaglia E, Ramay H, Barras D, Homicsko K, Maru D, Manyam GC, Broom B, Boige V, Perez-Villamil B, Laderas T, Salazar R, Gray JW, Hanahan D, Tabernero J, Bernards R, Friend SH, Laurent-Puig P, Medema JP, Sadanandam A, Wessels L, Delorenzi M, Kopetz S, Vermeulen L, Tejpar S. The consensus molecular subtypes of colorectal cancer. Nat. Med. 2015 Nov; 21(11): 1350-6
All publications
  • Ligero M, Garcia-Ruiz A, Viaplana C, Villacampa G, Raciti MV, Landa J, Matos I, Martin-Liberal J, Ochoa-de-Olza M, Hierro C, Mateo J, Gonzalez M, Morales-Barrera R, Suarez C, Rodon J, Elez E, Braña I, Muñoz-Couselo E, Oaknin A, Fasani R, Nuciforo P, Gil D, Rubio-Perez C, Seoane J, Felip E, Escobar M, Tabernero J, Carles J, Dienstmann R, Garralda E, Perez-Lopez R. A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. Radiology. 2021 Apr;299(1):109-119.
  • Llop-Guevara A, Loibl S, Villacampa G, Vladimirova V, Schneeweiss A, Karn T, Zahm DM, Herencia-Ropero A, Jank P, van Mackelenbergh M, Fasching PA, Marmé F, Stickeler E, Schem C, Dienstmann R, Florian S, Nekljudova V, Balmaña J, Hahnen E, Denkert C, Serra V. Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial. Ann Oncol. 2021 Dec;32(12):1590-1596.
  • Dienstmann R, Tamborero D. Genomic testing for targeted oncology drugs: hopes against hype. Ann Oncol. 2021 Jul;32(7):837-838.
  • Kulkarni AA, Naqash AR, Puri S, Dienstmann R. Is It Time to Implement Adjuvant Targeted Therapy in EGFR-Mutant Non-Small-Cell Lung Cancer? JCO Precis Oncol. 2021 Feb 17;5:PO.20.00460
  • Ros J, Baraibar I, Martini G, Salvà F, Saoudi N, Cuadra-Urteaga JL, Dienstmann R, Tabernero J, Élez E. The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer. Curr Treat Options Oncol. 2021 Nov 6;22(12):113.
  • Werutsky G, Barrios CH, Cardona AF, Albergaria A, Valencia A, Ferreira CG, Rolfo C, de Azambuja E, Rabinovich GA, Sposetti G, Arrieta O, Dienstmann R, Rebelatto TF, Denninghoff V, Aran V, Cazap E. Perspectives on emerging technologies, personalised medicine, and clinical research for cancer control in Latin America and the Caribbean. Lancet Oncol. 2021 Nov;22(11):e488-e500.
  • Gris-Oliver A, Ibrahim YH, Rivas MA, García-García C, Sánchez-Guixé M, Ruiz-Pace F, Viaplana C, Pérez-García JM, Llombart-Cussac A, Grueso J, Parés M, Guzmán M, Rodríguez O, Anton P, Cozar P, Calvo MT, Bruna A, Arribas J, Caldas C, Dienstmann R, Nuciforo P, Oliveira M, Cortés J, Serra V. PI3K activation promotes resistance to eribulin in HER2-negative breast cancer. Br J Cancer. 2021 Apr;124(9):1581-1591.
  • Sánchez-Guixé M, Hierro C, Jiménez J, Viaplana C, Villacampa G, Monelli E, Brasó-Maristany F, Ogbah Z, Parés M, Guzmán M, Grueso J, Rodríguez O, Oliveira M, Azaro A, Garralda E, Tabernero J, Casanovas O, Scaltriti M, Prat A, Dienstmann R, Nuciforo P, Saura C, Graupera M, Vivancos A, Rodon J, Serra V. High FGFR1-4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer. Clin Cancer Res. 2022 Jan 1;28(1):137-149.
  • Hernando-Calvo A, García-Alvarez A, Villacampa G, Ortiz C, Bodet D, García-Patos V, Recio JA, Dienstmann R, Muñoz-Couselo E. Dynamics of clinical biomarkers as predictors of immunotherapy benefit in metastatic melanoma patients. Clin Transl Oncol. 2021 Feb;23(2):311-317.
  • Saura C, Sánchez O, Martínez S, Domínguez C, Dienstmann R, Ruíz-Pace F, Céspedes MC, Peñuelas Á, Cortés J, Llurba E, Córdoba O. Evolution of Angiogenic Factors in Pregnant Patients with Breast Cancer Treated with Chemotherapy. Cancers (Basel). 2021 Feb 23;13(4):923.
  • De Mattos-Arruda L, Cortes J, Blanco-Heredia J, Tiezzi DG, Villacampa G, Gonçalves-Ribeiro S, Paré L, Souza CA, Ortega V, Sammut SJ, Cusco P, Fasani R, Chin SF, Perez-Garcia J, Dienstmann R, Nuciforo P, Villagrasa P, Rubio IT, Prat A, Caldas C. The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers. NPJ Breast Cancer. 2021 Jun 7;7(1):73.
  • Cedres S, Assaf JD, Iranzo P, Callejo A, Pardo N, Navarro A, Martinez-Marti A, Marmolejo D, Rezqallah A, Carbonell C, Frigola J, Amat R, Pedrola A, Dienstmann R, Felip E. Efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort. Sci Rep. 2021 Nov 1;11(1):21357.
  • Matos I, Villacampa G, Hierro C, Martin-Liberal J, Berché R, Pedrola A, Braña I, Azaro A, Vieito M, Saavedra O, Gardeazabal I, Hernando-Calvo A, Alonso G, Galvao V, Ochoa de Olza M, Ros J, Viaplana C, Muñoz-Couselo E, Elez E, Rodon J, Saura C, Macarulla T, Oaknin A, Carles J, Felip E, Tabernero J, Dienstmann R, Garralda E. Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials. Eur J Cancer. 2021 Sep;155:168-178.
  • Lafferty A, O’Farrell AC, Migliardi G, Khemka N, Lindner AU, Sassi F, Zanella ER, Salvucci M, Vanderheyden E, Modave E, Boeckx B, Halang L, Betge J, Ebert MPA, Dicker P, Argilés G, Tabernero J, Dienstmann R, Medico E, Lambrechts D, Bertotti A, Isella C, Trusolino L, Prehn JHM, Byrne AT. Molecular Subtyping Combined with Biological Pathway Analyses to Study Regorafenib Response in Clinically Relevant Mouse Models of Colorectal Cancer. Clin Cancer Res. 2021 Nov 1;27(21):5979-5992.
  • Ligero M, Jordi-Ollero O, Bernatowicz K, Garcia-Ruiz A, Delgado-Muñoz E, Leiva D, Mast R, Suarez C, Sala-Llonch R, Calvo N, Escobar M, Navarro-Martin A, Villacampa G, Dienstmann R, Perez-Lopez R. Minimizing acquisition-related radiomics variability by image resampling and batch effect correction to allow for large-scale data analysis. Eur Radiol. 2021 Mar;31(3):1460-1470.
  • Morgan G, Tagliamento M, Lambertini M, Devnani B, Westphalen B, Dienstmann R, Bozovic-Spasojevic I, Calles A, Criscitiello C, Curioni A, Garcia AM, Lamarca A, Pilotto S, Scheffler M, Strijbos M, Wong R, de Azambuja E, Peters S. Impact of COVID-19 on social media as perceived by the oncology community: results from a survey in collaboration with the European Society for Medical Oncology (ESMO) and the OncoAlert Network. ESMO Open. 2021 Apr;6(2):100104.
  • Kehl KL, Riely GJ, Lepisto EM, Lavery JA, Warner JL, LeNoue-Newton ML, Sweeney SM, Rudolph JE, Brown S, Yu C, Bedard PL, Schrag D, Panageas KS; American Association of Cancer Research (AACR) Project Genomics Evidence Neoplasia Information Exchange (GENIE) Consortium. Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Non-Small Cell Lung or Colorectal Cancer. JAMA Netw Open. 2021 Jul 1;4(7):e2117547.
  • Villacampa G, Dienstmann R, Bosch F, Abrisqueta P. Combination of novel molecular targeted agent plus R-CHOP-based regimen versus R-CHOP alone in previously untreated diffuse large B-cell lymphoma (DLBCL) patients: a systematic review and meta-analysis. Ann Hematol. 2021 Dec;100(12):2969-2978.
  • López-Fernández A, Villacampa G, Grau E, Salinas M, Darder E, Carrasco E, Torres-Esquius S, Iglesias S, Solanes A, Gadea N, Velasco A, Urgell G, Torres M, Tuset N, Brunet J, Corbella S, Balmaña J. Patients’ and professionals’ perspective of non-in-person visits in hereditary cancer: predictors and impact of the COVID-19 pandemic. Genet Med. 2021 Aug;23(8):1450-1457.
  • Iacoboni G, Simó M, Villacampa G, Catalá E, Carpio C, Díaz-Lagares C, Vidal-Jordana Á, Bobillo S, Marín-Niebla A, Pérez A, Jiménez M, Abrisqueta P, Bosch F, Barba P. Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy. Ann Hematol. 2021 Sep;100(9):2303-2310.
  • Ortí G, Palacio-Garcia C, García-Cadenas I, Sánchez-Ortega I, Jimenez MJ, Azqueta C, Villacampa G, Ferrà C, Parody R, Martino R, Bosch F, Querol S, Valcárcel D. Analysis of Cell Subsets in Donor Lymphocyte Infusions from HLA Identical Sibling Donors after Allogeneic Hematopoietic Cell Transplant. Transplant Cell Ther. 2021 Jan;27(1):53.e1-53.e8.
  • Quintana Á, Peg V, Prat A, Moliné T, Villacampa G, Paré L, Galván P, Dientsmann R, Schmid P, Curigliano G, Muñoz-Couselo E, Perez-García J, Marti M, Blanco-Heredia J, Anjos CD, Vazquez M, De Mattos-Arruda L, Cortés J. Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer. Eur J Cancer. 2021 May;148:134-145.
  • Elez E, Ayala F, Felip E, García Campelo R, García Carbonero R, García Donás J, González Del Alba A, González Flores E, Hidalgo J, Isla D, Majem M, Rodríguez Lescure Á, Safont MJ, Santaballa A, Villacampa G, Vera R, Garrido P. Gender influence on work satisfaction and leadership for medical oncologists: a survey of the Spanish Society of Medical Oncology (SEOM). ESMO Open. 2021 Apr;6(2):100048.
  • Pascual T, Oliveira M, Ciruelos E, Bellet Ezquerra M, Saura C, Gavilá J, Pernas S, Muñoz M, Vidal MJ, Margelí Vila M, Cejalvo JM, González-Farré B, Espinosa-Bravo M, Cruz J, Salvador-Bofill FJ, Guerra JA, Luna Barrera AM, Arumi de Dios M, Esker S, Fan PD, Martínez-Sáez O, Villacampa G, Paré L, Ferrero-Cafiero JM, Villagrasa P, Prat A. SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer. Front Oncol. 2021 Apr 23;11:638482.
  • Carpio C, Iacoboni G, Villacampa G, Catalá E, Bobillo S, Pérez A, Jiménez M, Segura L, Olivé M, Farriols A, Abrisqueta P, Valcárcel D, Carreras MJ, Bosch F, Barba P. Selection process and causes of non-eligibility for CD19 CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma in a European center. Leuk Lymphoma. 2021 Sep;62(9):2288-2291.
  • Vila CM, Moreno FA, Estébanez MM, Ares GR, Villacampa G, Dashti P, Oberoi HS, Martin-Huertas R, Jares P, Alos L, Teixido C, Rull R, Sanchez M, Malvehy J, Carcelero E, Valduvieco I, Fernandez AA. Exploratory analysis of clinical benefit of ipilimumab and nivolumab treatment in patients with metastatic melanoma from a single institution. Clin Transl Oncol. 2022 Feb;24(2):319-330.
  • Iacoboni G, Villacampa G, Martinez-Cibrian N, Bailén R, Lopez Corral L, Sanchez JM, Guerreiro M, Caballero AC, Mussetti A, Sancho JM, Hernani R, Abrisqueta P, Solano C, Sureda A, Briones J, Martin Garcia-Sancho A, Kwon M, Reguera-Ortega JL, Barba P; GETH, GELTAMO Spanish Groups. Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma. Cancer Med. 2021 May;10(10):3214-3223.
  • Evidence-based neoadjuvant endocrine therapy for breast cancer Dienstmann R, Bines J. Clin Breast Cancer 2006;7(4):315-20.
  • Phase II trial of neoadjuvant chemotherapy using alternating doublets in non-small cell lung cancer Martins RG, Dienstmann R, Biasi P, Dantas K, Santos VO, Toscano E, Roriz W, Zamboni M, Sousa A, Ferreira CG, Small I, Moreira D, Zukin M. Clin Lung Cancer 2007;8(4):257-63.
  • Phase II trial of neoadjuvant gemcitabine and cisplatin in patients with invasive bladder carcinoma Herchenhorn D, Dienstmann R, Peixoto FA, Campos FS, Santos VO, Moreira DM, Cardoso H, Small I, Ferreira CG. Int Braz J Urol 2007;33(5):630-8.
  • Palliative percutaneous nephrostomy in recurrent cervical cancer: Retrospective analysis of 50 consecutive cases Dienstmann R, Pinto CS, Pereira MT, Small I, Ferreira CG. J Pain Symptom Manage 2008;36(2):185-90.
  • XAF1 mRNA expression improves progression-free and overall survival for patients with advanced bladder cancer treated with neoadjuvant chemotherapy Pinho MB, Costas F, Sellos J, Dienstmann R, Andrade PB, Herchenhorn D, Peixoto FA, Santos VO, Small IA, Guimarães DP, Ferreira CG. Urol Oncol 2009;27(4):382-90.
  • Necitumumab (IMC-11F8), a fully human IgG1 mAb directed against epidermal growth factor receptor for the intravenous treatment of cancer Dienstmann R, Tabernero J. Curr Opin Investig Drugs 2010;11(12):1434-41.
  • Recent developments in anti-cancer Agents targeting PI3K, Akt and mTORC1/2 Dienstmann R, Rodon J, Tabernero J. Recent Pat Anticancer Drug Discov 2011;6(2):210-36.
  • Targeting the PI3K-Akt-mTOR pathway – beyond rapalogs Markman B, Dienstmann R, Tabernero J. Oncotarget 2010;1(7):530-43.
  • BRAF as a target for cancer therapy Dienstmann R, Tabernero J. Anticancer Agents Med Chem 2011;11(3):285-95.
  • Molecular predictors of response to chemotherapy in colorectal cancer Dienstmann R, Vilar E, Tabernero J. Cancer J 2011;17(2):114-26.
  • Personalizing therapy with targeted agents in non-small cell lung cancer Dienstmann R, Martinez P, Felip E. Oncotarget 2011;2(3):165-77.
  • Combined modality therapy of stage IIIC breast cancer Dienstmann R, Branco LG, Rezende LM, Freitas LC, Lima CF, Rodrigues GJ, Noronha Filho H, Sarmento RMB, Small I, Bines J. Breast J 2011;17(3):331-3.
  • Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development Dienstmann R, Felip E. Expert Opin Biol Ther 2011;11(9):1223-31.
  • The development of molecular biomarkers in the individualized treatment of colorectal cancer De Mattos-Arruda L, Dienstmann D, Tabernero J. Clin Colorectal Cancer 2011;10(4):279-89.
  • Risk-benefit assessment of bevacizumab in the treatment of breast cancer Dienstmann R, Ades F, Saini KS, Metzger-Filho O. Drug Saf 2012;35(1):15-25.
  • Toxicity as biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGFR inhibiting anticancer agents Dienstmann R, Braña I, Rodon J, Tabernero J. Oncologist 2011;16(12):1729-40.
  • Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer Dienstmann R, De Dosso S, Felip E, Tabernero J. Mol Oncol 2012;6(1):15-26.
  • Application of monoclonal antibodies as cancer therapy in solid tumors Dienstmann R, Markman B, Tabernero J. Curr Clin Pharmacol 2012;7(2):137-45.
  • Panitumumab: summary of clinical development in colorectal cancer and future directions Argiles G, Dienstmann R, Tabernero J. Future Oncol 2012;8(4):373-89.
  • Molecular prescreening to select patient population in early clinical trials Rodón J, Saura C, Dienstmann R, Vivancos A, Cajal SR, Baselga J, Tabernero J. Nat Rev Clin Oncol 2012;9(6):359-66
  • Molecular profiling of patients with colorectal cancer and matched targeted therapy in Phase 1 clinical trials Dienstmann R, Serpico D, Rodon J, Saura C, Macarulla T, Elez ME, Alsina M, Capdevila J, Perez-Garcia J, Sánchez-Ollé G, Aura C, Prudkin L, Landolfi S, Hernández-Losa J, Vivancos A, Tabernero J. Mol Cancer Ther 2012;11(9):2062-71.
  • Drug development in the era of personalized oncology: from population-based trials to enrichment and prescreening strategies Dienstmann R, Rodon J, Tabernero J. Am Soc Clin Oncol Educ Book 2012;32:168-72.
  • Development of PI3K inhibitors: lessons learned from early clinical trials. Rodon J, Dienstmann R, Serra V, Tabernero J. Nat Rev Clin Oncol 2013;10(3):143-53.
  • Biomarker-driven patient selection for early clinical trials Dienstmann R, Rodon J, Barretina J, Tabernero J. Curr Opin Oncol 2013;25(3):305-12.
  • The genomic medicine frontier in human solid tumors: prospects and challenges Dienstmann R, Rodon J, Barretina J, Tabernero J. J Clin Oncol 2013;31(15):1874-84.
  • Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors Dienstmann R, Rodon J, Prat A, Perez-Garcia J, Adamo B, Felip E, Cortes J, Iafrate AJ, Nuciforo P, Tabernero J Annals Oncol 2014;25(3):552-63. 
  • Activity of megestrol acetate in postmenopausal women with advanced breast cancer after nonsteroidal aromatase inhibitor failure: a phase II trial Bines J, Dienstmann R, Obadia RM, Branco LGB, Quintella DC, Castro TM, Camacho PG, Soares F, Costa MEF Annals Oncol 2014;25(4):831-6.
  • Tumor Growth Rate (TGR) analysis in Phase I clinical trials–Letter. Dienstmann R, Tabernero J Clin Cancer Res 2014;20(9):2495-6.
  • Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors Dienstmann R, Rodon J, Serra V, Tabernero J Mol Cancer Ther 2014;13(5):1021-31.
  • Standardized decision support in sequencing reports of somatic cancer variants Dienstmann R, Dong F, Borger D, Dias-Santagata D, Ellisen LW, Le LP, Iafrate AJ Mol Oncol 2014;8(5):859-873.
  • The evolution of our molecular understanding of colorectal cancer: what we are doing now, what the future holds, and how tumor profiling is just the beginning DienstmannR, Salazar R, Tabernero J Am Soc Clin Oncol Educ Book 2014;34:91-9.
  • Optimal design of trials to demonstrate the utility of genomically-guided therapy: putting Precision Cancer Medicine to the test Dienstmann R, Rodon J, Tabernero J Mol Oncol 2014;S1574-7891(14)00150-1.
  • Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors Soria JC, DeBraud F, Bahleda R, Adamo B, Andre F, Dienstmann R, Delmonte A, Cereda R, Isaacson J, Litten J, Allen A, Dubois F, Saba C, Robert R, D’Incalci M, Zucchetti M, Camboni MG, Tabernero Ann Oncol 2014;25(11):2244-51.
  • Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes Sinicrope FA, Shi Q, Smyrk TC, Thibodeau SN, Dienstmann R, Guinney J, Bot BM, Tejpar S, Delorenzi M, Goldberg RM, Mahoney M, Sargent DJ, Alberts SR. Gastroenterology 2015;148(1):88-99.
  • Social interactomes for enabling research communities Guinney J, Dienstmann R, Ferté C, Friend S, McCormick F Cancer Discov 2014;4(11):1265-8.
  • Stepwise group sparse regression (SGSR): gene-set-based pharmacogenomic predictive models with stepwise selection of functional priors. Jang IS, Dienstmann R, Margolin AA, Guinney J. Pac Symp Biocomput 2015;20:32-43.
  • Intrinsic cancer subtypes – next steps into personalized medicine. Santos C, Sanz-Pamplona R, Nadal E, Grasselli J, Pernas S, Dienstmann R, Moreno V, Tabernero J, Salazar R. Cell Oncol (Dordr) 2015;38(1):3-16.
  • Genomic testing in colorectal cancer: how much is enough? Dienstmann R, Salazar R, Tabernero J. Oncology (Williston Park) 2015;29(3):186-8.
  • A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3. Mau-Sørensen M, Dittrich C, Dienstmann R, Lassen U, Büchler W, Martinius H, Tabernero J. Cancer Chemother Pharmacol 2015;75(5):1065-73.
  • Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors Dienstmann R, Jang IS, Bot B, Friend S, Guinney J Cancer Discovery 2015;5(2):118-23.
  • Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients DienstmannR, Salazar R, Tabernero J J Clin Oncol 2015; 33(16):1787-96.
  • Safety and pharmacokinetics/pharmacodynamics of the first-in-class dual action HER3/EGFR antibody MEHD7945A in patients with locally advanced or metastatic epithelial tumors Juric D, Dienstmann R, Cervantes A, Hidalgo M, Messersmith W, Blumenschein Jr. GR, Tabernero J, Roda D, Calles A, Jimeno A, Wang A, Bohórquez SS, Leddy C, Littman C, Kapp AV, Shames DS, Penuel E, Amler LC, Pirzkall A, Baselga J Clin Cancer Res 2015;21(11):2462-70.
  • Heterogeneity of driver genes and therapeutic implications in colorectal cancer Dienstmann R, Cervantes A Annals Oncol 2015;26(8):1523-5.
  • Overcoming Resistance to anti-EGFR Therapy in Colorectal Cancer Dienstmann R, Salazar R, Tabernero J Am Soc Clin Oncol Educ Book 2015;35:e149-56.
  • Safety and activity of the first-in-class Sym004 anti-EGFR antibody mixture in patients with refractory colorectal cancer Dienstmann R, Patnaik A, Garcia-Carbonero R, Cervantes A, Benavent M, Roselló S, Tops BB, van der Post RS, Argilés G, Skartved NJ, Hansen UH, Hald R, Pedersen MW, Kragh M, Horak ID, Braun S, Van Cutsem E, Tolcher AW, Tabernero J. Cancer Discov 2015;5(6):598-609.
  • Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced solid tumors. Tabernero J, Bahleda R, Dienstmann R, Infante JR, Mita A, Italiano A, Calvo E, Moreno V, Adamo B, Gazzah A, Zhong B, Platero SJ, Smit H, Stuyckens K, Chatterjee-Kishore M, Rodon J, Peddareddigari V, Luo FR, Soria J-C J Clin Oncol 2015;33(30):3401-8.
  • The consensus molecular subtypes of colorectal cancer Guinney J,Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, Bot BM, Morris JS, Simon IM, Gerster S, Fessler E, De Sousa E Melo F, Missiaglia E, Ramay H, Barras D, Homicsko K, Maru D, Manyam GC, Broom B, Boige V, Perez-Villamil B, Laderas T, Salazar R, Gray JW, Hanahan D, Tabernero J, Bernards R, Friend SH, Laurent-Puig P, Medema JP, Sadanandam A, Wessels L, Delorenzi M, Kopetz S, Vermeulen L, Tejpar S. Nat Med 2015;21(11):1350-6.
  • MEK plus PI3K/mTORC1/2 therapeutic efficacy is impacted by TP53 mutation in preclinical models of colorectal cancer García-García C, Rivas MA, Ibrahim YH, Calvo MT, Gris-Oliver A, Rodríguez O, Grueso J, Antón P, Guzmán M, Aura C, Nuciforo P, Jessen K, Argilés G,Dienstmann R, Bertotti A, Trusolino L, Matito J, Vivancos A, Chicote I, Palmer HG, Tabernero J, Scaltriti M, Baselga J, Serra V. Clin Cancer Res 2015;21(24):5499-510.
  • Tankyrase inhibition blocks Wnt/β-catenin pathway and reverts resistance to PI3K and AKT inhibitors in the treatment of colorectal cancer. Arques O, Chicote I, Puig I, Tenbaum SP, Argiles G,Dienstmann R, Fernandez N, Caratu G, Matito J, Silberschmidt D, Rodon J, Landolfi S, Prat A, Espin E, Charco R, Nuciforo P, Vivancos A, Shao W, Tabernero J, Palmer HG. Clin Cancer Res 2016;22(3):644-56. 
  • First-in-man dose-escalation study of the selective BRAF inhibitor RG7256 in patients with BRAF V600-mutated advanced solid tumors Dienstmann R, Lassen U, Cebon J, Desai J, Brown MP, Evers S, Su F, Zhang W, Doisserie F, Lestini B, Schostack K, Meresse V, Tabernero J Target Oncol 2016;11(2):149-56.
  • Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies. Azuara D, Santos C, Lopez-Doriga A, Grasselli J, Nadal M, Sanjuan X, Marin F, Vidal J, Montal R, Moreno V, Bellosillo B, Argiles G, Elez E, DienstmannR, Montagut C, Tabernero J, Capellá G, Salazar R. Mol Cancer Ther 2016;15(5):1106-12.
  • Spectrum of Gene Mutations in Colorectal Cancer: Implications for Treatment. Dienstmann R, Tabernero J. Cancer J 2016;22(3):149-55.
  • CIViC: A knowledgebase for expert-crowdsourcing the clinical interpretation of variants in cancer Griffith M, Spies NC, Krysiak K, Coffman AC, McMichael JF, Ainscough BJ, Rieke DJ, Danos AM, Kujan L, Ramirez CA, Wagner AH, Skidmore ZL, Liu CJ, Jones M, Bilski RL, Lesurf R, Barnell EK, Shah NM, Bonakdar M, Trani L, Matlock M, Ramu A, Campbell KM, Spies GC, Graubert AP, Karthik G, Eldred JM, Larson DE, Walker JR, Chu S, Bryan JN, Good BN, Wu C, Su AI, Dienstmann R, Jones SJM, Bose R, Spencer DH, Wartman LD, Wilson RK, Mardis ER, Griffith OL. Nat Genetics 2017;49(2):170-174.
  • Consensus Molecular Subtyping and the Evolution of Precision Medicine in Colorectal Cancer Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J. Nat Rev Cancer 2017;7(2):79-92.
  • Prediction of overall survival in stage II and III colon cancer beyond the American Joint Commission on Cancer TNM system: a retrospective, pooled biomarker study Dienstmann R, Mason MJ, Sinicrope FA, Phipps AI, Tejpar S, Nesbakken A, Danielsen SA, Sveen A, Buchanan DD, Clendenning M, Rosty C, Bot B, Alberts SR, Milburn Jessup J, Lothe RA, Delorenzi M, Newcomb PA, Sargent D, Guinney J. Ann Oncol 2017;28(5):1023-1031.
  • Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer. Grasselli J, Elez E, Caratù G, Matito J, Santos C, Macarulla T, Vidal J, Garcia M, Viéitez JM, Paéz D, Falcó E, Lopez Lopez C, Aranda E, Jones F, Sikri V, Nuciforo P, Fasani R, Tabernero J, Montagut C, Azuara D, Dienstmann R, Salazar R, Vivancos A. Ann Oncol 2017 Jun 1;28(6):1294-1301.
  • Pharmacokinetic/Pharmacodynamic Modeling for Drug Development in Oncology. Garralda E, Dienstmann R, Tabernero J. Am Soc Clin Oncol Educ Book 2017;37:210-215.
  • Personalizing Adjuvant Therapy for Stage II/III Colorectal Cancer. McCleary NJ, Benson AB 3rd, Dienstmann R. Am Soc Clin Oncol Educ Book 2017;37:232-245.
  • Analysis of mutant allele fractions in driver genes in colorectal cancer – biological and clinical insights. Dienstmann R, Elez E, Argiles G, Matos I, Sanz-Garcia E, Ortiz C, Macarulla T, Capdevila J, Alsina M, Sauri T, Verdaguer H, Vilaro M, Ruiz-Pace F, Viaplana C, Garcia A, Landolfi S, Palmer HG, Nuciforo P, Rodon J, Vivancos A, Tabernero J. Mol Oncol 2017;11(9):1263-1272.
  • Genomic Determinants of Protein Abundance Variation in Colorectal Cancer Cells. Roumeliotis TI, Williams SP, Gonçalves E, Alsinet C, Del Castillo Velasco-Herrera M, Aben N, Ghavidel FZ, Michaut M, Schubert M, Price S, Wright JC, Yu L, Yang M, Dienstmann R, Guinney J, Beltrao P, Brazma A, Pardo M, Stegle O, Adams DJ, Wessels L, Saez-Rodriguez J, McDermott U, Choudhary JS. Cell Rep 2017;20(9):2201-2214.
  • Cancer: A precision approach to tumour treatment. Dienstmann R, Tabernero J. Nature 2017;548(7665):40-41.
  • Reply to the letter to the editor ‘Including lynch syndrome in personalized prognostication and follow-up of stage II and III colon cancer’ by Sciallero et al. Dienstmann R, Guinney J. Annals Oncol 2017;28(11)2889-2890.
  • Tumor side as model of integrative molecular classification of colorectal cancer. Dienstmann Clin Cancer Res 2018;24(5):989-990.
  • Colorectal cancer Consensus Molecular Subtypes translated to preclinical models uncover potentially targetable cancer-cell dependencies. Sveen A, Bruun J, Eide PW, Eilertsen IA, Ramirez L, Murumägi A, Arjama MA, Danielsen SA, Kryeziu K, Elez E, Tabernero J, Guinney J, Palmer HG, Nesbakken A, Kallioniemi O,Dienstmann R, Lothe RA. Clin Cancer Res 2018;24(4):794-806.
  • Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial. Montagut C, Argilés G, Ciardiello F, Poulsen TT, DienstmannR, Kragh M, Kopetz S, Lindsted T, Ding C, Vidal J, Clausell-Tormos J, Siravegna G, Sánchez-Martín FJ, Koefoed K, Pedersen MW, Grandal MM, Dvorkin M, Wyrwicz L, Rovira A, Cubillo A, Salazar R, Desseigne F, Nadal C, Albanell J, Zagonel V, Siena S, Fumi G, Rospo G, Nadler P, Horak ID, Bardelli A, Tabernero J. JAMA Oncol 2018:e175245.
  • CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer. Smeby J, Sveen A, Merok MA, Danielsen SA, Eilertsen IA, Guren MG, DienstmannR, Nesbakken A, Lothe RA. Ann Oncol 2018; 29(5):1227-1234
  • Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations. Tamborero D, Rubio-Perez C, Deu-Pons J, Schroeder MP, Vivancos A, Rovira A, Tusquets I, Albanell J, Rodon J, Tabernero J, de Torres C, DienstmannR, Gonzalez-Perez A, Lopez-Bigas N. Genome Med 2018;10(1):25.
  • TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence Puig I, Tenbaum SP, Chicote I, Arqués O, Martínez-Quintanilla J, Cuesta-Borrás E, Ramírez L, Gonzalo P, Soto A, Aguilar S, Eguizabal C, Caratù G, Prat A, Argilés G, Landolfi S, Casanovas O, Serra V, Villanueva A, Arroyo AG, Terracciano L, Nuciforo P, Seoane J, Recio JA, Vivancos A, Dienstmann R, Tabernero J, Palmer HG. J Clin Invest. 2018 Jun 26. pii: 96393.
  • A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations. Tamborero D, Rubio-Perez C, Muiños F, Sabarinathan R, Piulats JM, Muntasell A, Dienstmann R, Lopez-Bigas N, Gonzalez-Perez A. Clin Cancer Res 2018;24(15):3717-3728.
  • Molecular Subtypes and the Evolution of Treatment Decisions in Metastatic Colorectal Cancer. Dienstmann R, Salazar R, Tabernero J. Am Soc Clin Oncol Educ Book 2018;(38):231-238.
  • Transcriptional subtyping and CD8 immunohistochemistry identifies poor prognosis stage II/III colorectal cancer patients who benefit from adjuvant chemotherapy. Allen WL, Dunne PD, McDade S, Scanlon E, Loughrey M, Coleman H, McCann C, McLaughlin K, Nemeth Z, Syed N, Jithesh P, Arthur K, Wilson R, Coyle V, McArt D, Murray GI, Samuel L, Nuciforo P, Jimenez J, Argiles G, Dienstmann R, Tabernero J, Messerini L, Nobili S, Mini E, Sheahan K, Ryan E, Johnston PG, Van Schaeybroeck S, Lawler M, Longley DB. JCO Precis Oncol 2018; Jun 13
  • Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2. Chang K, Willis JA, Reumers J, Taggart MW, San Lucas FA, Thirumurthi S, Kanth P, Delker DA, Hagedorn CH, Lynch PM, Ellis LM, Hawk ET, Scheet PA, Kopetz S, Arts J, Guinney J, Dienstmann R, Vilar E. Ann Oncol 2018;29(10):2061-2067.
  • A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, Ng CKY, Bedard PL, Tortora G, Douillard JY, Van Allen EM, Schultz N, Swanton C, André F, Pusztai L. Ann Oncol 2018; 29(9):1895-1902
  • Should next-generation sequencing testing be routinely used in metastatic colorectal cancer? Dienstmann R, Ciner A, Hochster HS. Lancet Oncol 2018;19(11):1434-1435
  • Precision oncology: separating the wheat from the chaff. Remon J, Dienstmann R. ESMO Open 2018;3(6):e000446.
  • A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. Castroviejo-Bermejo M, Cruz C, Llop-Guevara A, Gutiérrez-Enríquez S, Ducy M, Ibrahim YH, Gris-Oliver A, Pellegrino B, Bruna A, Guzmán M, Rodríguez O, Grueso J, Bonache S, Moles-Fernández A, Villacampa G, Viaplana C, Gómez P, Vidal M, Peg V, Serres-Créixams X, Dellaire G, Simard J, Nuciforo P, Rubio IT, Dienstmann R, Barrett JC, Caldas C, Baselga J, Saura C, Cortés J, Déas O, Jonkers J, Masson JY, Cairo S, Judde JG, O’Connor MJ, Díez O, Balmaña J, Serra V. EMBO Mol Med 2018;10(12).
  • New clinical trial designs in the era of precision medicine. Garralda E, Dienstmann R, Piris-Giménez A, Braña I, Rodon J, Tabernero J.Mol Oncol 2019;13(3):549-557.
  • Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer. Rodriguez-Freixinos V, Ruiz-Pace F, Fariñas-Madrid L, Garrido-Castro AC, Villacampa G, Nuciforo P, Vivancos A, Dienstmann R, Oaknin A. ESMO Open 2019;4(2):e000444
  • Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients. Rodriguez-Freixinos V, Fariñas-Madrid L, Gil-Martin M, Barretina-Ginesta P, Romeo M, Villacampa G, Pardo B, Ahmed H, Recalde S, Piulats JM, Gómez-Plaza MC, Gil-Moreno A, Sala E, Martínez-Román S, Ponce J, Meléndez C, Carballas E, Dienstmann R, Oaknin A. Gynecol Oncol 2019;152(2):270-277.
  • Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer. Serna G, Ruiz-Pace F, Cecchi F, Fasani R, Jimenez J, Thyparambil S, Landolfi S, Elez ME, Vivancos A, Hembrough T, Tabernero J, Dienstmann R, Nuciforo P. Sci Rep 2019;9(1):13568.
  • Predictive modeling in colorectal cancer: time to move beyond consensus molecular subtypes. Sveen A, Cremolini C, Dienstmann R. Ann Oncol 2019;30(11):1682-1685.
  • Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer.Dienstmann R, Villacampa G, Sveen A, Mason MJ, Niedzwiecki D, Nesbakken A, Moreno V, Warren RS, Lothe RA, Guinney J. Ann Oncol 2019;30(10):1622-1629.
  • Capturing Hyperprogressive disease with immune checkpoint inhibitors using RECIST 1.1 criteria. Matos I, Martin-Liberal J, Garcia-Ruiz A, Hierro C, Ochoa de Olza M, Viaplana C, Azaro A, Vieito M, Brana I, Mur G, Ros J, Mateos J, Villacampa G, Berché R, Oliveira M, Alsina M, Élez E, Oaknin A, Muñoz-Couselo E, Carles J, Felip E, Rodon J, Tabernero J, Dienstmann R, Perez-Lopez R, Garralda E. Clin Cancer Res 2020;26(8):1846-1855.
  • Precision Therapy in RAS Mutant Colorectal Cancer. Dienstmann R, Connor K, Byrne AT; COLOSSUS Consortium. Gastroenterology 2020;158(4):806-811.
  • A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer. Wagner AH, Walsh B, Mayfield G, Tamborero D, Sonkin D, Krysiak K, Deu-Pons J, Duren RP, Gao J, McMurry J, Patterson S, Del Vecchio Fitz C, Pitel BA, Sezerman OU, Ellrott K, Warner JL, Rieke DT, Aittokallio T, Cerami E, Ritter DI, Schriml LM, Freimuth RR, Haendel M, Raca G, Madhavan S, Baudis M, Beckmann JS, Dienstmann R, Chakravarty D, Li XS, Mockus S, Elemento O, Schultz N, Lopez-Bigas N, Lawler M, Goecks J, Griffith M, Griffith OL, Margolin AA; Variant Interpretation for Cancer Consortium. Nat Genet 2020;52(4):448-457.
  • Evolving Landscape of Molecular Prescreening Strategies for Oncology Early Clinical Trials. Dienstmann R, Garralda E, Aguilar S, Sala G, Viaplana C, Ruiz-Pace F, González-Zorelle J, Grazia LoGiacco D, Ogbah Z, Ramos Masdeu L, Mancuso F, Fasani R, Jimenez J, Martinez P, Oaknin A, Saura C, Oliveira M, Balmaña J, Carles J, Macarulla T, Elez E, Alsina M, Braña I, Felip E, Tabernero J, Rodon J, Nuciforo P, Vivancos A. JCO Precis Oncol 2020;4:PO.19.00398.
  • Patient-derived organoids from multiple colorectal cancer liver metastases reveal moderate intra-patient pharmacotranscriptomic heterogeneity. Bruun J, Kryeziu K, Eide PW, Moosavi SH, Eilertsen IA, Langerud J, Røsok BI, Totland MZ, Brunsell TH, Pellinen T, Saarela J, Bergsland CH, Palmer HG, Brudvik KW, Guren T, Dienstmann R, Guren MG, Nesbakken A, Bjørnbeth BA, Sveen A, Lothe RA. Clin Cancer Res 2020, 26(15):4107-4119.
  • Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients. Cedrés S, Ponce-Aix S, Iranzo P, Callejo A, Pardo N, Navarro A, Martinez- Marti A, Gómez-Abecia S, Zucchiatti AC, Sansano I, Enguita AB, Miquel JM, Viaplana C, Dienstmann R, Paz-Ares L, Felip E. Clin Transl Oncol 2020;22(8):1390-1398.
  • Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal. Tamborero D, Dienstmann R, Rachid MH, Boekel J, Baird R, Braña I, De Petris L, Yachnin J, Massard C, Opdam FL, Schlenk R, Vernieri C, Garralda E, Masucci M, Villalobos X, Chavarria E; Cancer Core Europe consortium, Calvo F, Fröhling S, Eggermont A, Apolone G, Voest EE, Caldas C, Tabernero J, Ernberg I, Rodon J, Lehtiö J. Nat Med 2020;26(7):992-994.
  • Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, Normanno N, Scarpa A, Robson M, Meric-Bernstam F, Wagle N, Stenzinger A, Bonastre J, Bayle A, Michiels S, Bièche I, Rouleau E, Jezdic S, Douillard JY, Reis-Filho JS, Dienstmann R, André F. Ann Oncol 2020;S0923-7534(20):39971-3.
  • Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts. Gris-Oliver A, Palafox M, Monserrat L, Brasó-Maristany F, Òdena A, Sánchez-Guixé M, Ibrahim YH, Villacampa G, Grueso J, Parés M, Guzmán M, Rodríguez O, Bruna A, Hirst CS, Barnicle A, de Bruin EC, Reddy A, Schiavon G, Arribas J, Mills GB, Caldas C, Dienstmann R, Prat A, Nuciforo P, Razavi P, Scaltriti M, Turner NC, Saura C, Davies BR, Oliveira M, Serra V. Clin Cancer Res 2020 ;26(14):3720-3731.
  • Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction. Stjepanovic N, Villacampa G, Nead KT, Torres-Esquius S, Melis GG, Nathanson KL, Teule A, Brunet J, Y Cajal TR, Llort G, Dienstmann R, Rue M, Domchek SM, Balmaña J. Eur J Cancer 2020;132:53-60.
  • Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype. Lupo B, Sassi F, Pinnelli M, Galimi F, Zanella ER, Vurchio V, Migliardi G, Gagliardi PA, Puliafito A, Manganaro D, Luraghi P, Kragh M, Pedersen MW, Horak ID, Boccaccio C, Medico E, Primo L, Nichol D, Spiteri I, Heide T, Vatsiou A, Graham TA, Élez E, Argiles G, Nuciforo P, Sottoriva A, Dienstmann R, Pasini D, Grassi E, Isella C, Bertotti A, Trusolino L. Sci Transl Med 2020;12(555):eaax8313.
  • Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer. Serna G, Ruiz-Pace F, Hernando J, Alonso L, Fasani R, Landolfi S, Comas R, Jimenez J, Elez E, Bullman S, Tabernero J, Capdevila J, Dienstmann R, Nuciforo P. Ann Oncol 2020;31(10):1366-1375.
  • Correlation of the tumour-stroma ratio with diffusion weighted MRI in rectal cancer. Zunder SM, Perez-Lopez R, de Kok BM, Raciti MV, van Pelt GW, Dienstmann R, Garcia-Ruiz A, Meijer CA, Gelderblom H, Tollenaar RA, Nuciforo P, Wasser MN, Mesker WE. Eur J Radiol 2020;133:109345.
  • Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer. Martini G, Dienstmann R, Ros J, Baraibar I, Cuadra-Urteaga JL, Salva F, Ciardiello D, Mulet N, Argiles G, Tabernero J, Elez E. Ther Adv Med Oncol 2020;12:1758835920936089.
  • RBMS1 Suppresses Colon Cancer Metastasis through Targeted Stabilization of Its mRNA Regulon. Yu J, Navickas A, Asgharian H, Culbertson B, Fish L, Garcia K, Olegario JP, Dermit M, Dodel M, Hänisch B, Luo Y, Weinberg EM, Dienstmann R, Warren RS, Mardakheh FK, Goodarzi H. Cancer Discov 2020;10(9):1410-1423.
  • A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. Ligero M, Garcia-Ruiz A, Viaplana C, Villacampa G, Raciti MV, Landa J, Matos I, Martin-Liberal J, Ochoa-de-Olza M, Hierro C, Mateo J, Gonzalez M, Morales-Barrera R, Suarez C, Rodon J, Elez E, Braña I, Muñoz-Couselo E, Oaknin A, Fasani R, Nuciforo P, Gil D, Rubio-Perez C, Seoane J, Felip E, Escobar M, Tabernero J, Carles J, Dienstmann R, Garralda E, Perez-Lopez R. Radiology 2021:200928.
  • Determinants of COVID-19 Mortality in Patients With Cancer From a Community Oncology Practice in Brazil. Ferrari BL, Ferreira CG, Menezes M, De Marchi P, Canedo J, Melo AC, Jácome AA, Reinert T, Paes RD, Sodré B, Barrios CH, Dienstmann R. JCO Glob Oncol 2021;7:46-55.
  • Dynamics of clinical biomarkers as predictors of immunotherapy benefit in metastatic melanoma patients. Hernando-Calvo A, García-Alvarez A, Villacampa G, Ortiz C, Bodet D, García-Patos V, Recio JA, Dienstmann R, Muñoz-Couselo E. Clin Transl Oncol 2021;23(2):311-317.
  • Minimizing acquisition-related radiomics variability by image resampling and batch effect correction to allow for large-scale data analysis. Ligero M, Jordi-Ollero O, Bernatowicz K, Garcia-Ruiz A, Delgado-Muñoz E, Leiva D, Mast R, Suarez C, Sala-Llonch R, Calvo N, Escobar M, Navarro-Martin A, Villacampa G, Dienstmann R, Perez-Lopez R. Eur Radiol 2021;31(3):1460-1470.
  • PI3K activation promotes resistance to eribulin in HER2-negative breast cancer. Gris-Oliver A, Ibrahim YH, Rivas MA, García-García C, Sánchez-Guixé M, Ruiz-Pace F, Viaplana C, Pérez-García JM, Llombart-Cussac A, Grueso J, Parés M, Guzmán M, Rodríguez O, Anton P, Cozar P, Calvo MT, Bruna A, Arribas J, Caldas C, Dienstmann R, Nuciforo P, Oliveira M, Cortés J, Serra V. Br J Cancer 2021 Mar 15.
  • Evolution of Angiogenic Factors in Pregnant Patients with Breast Cancer Treated with Chemotherapy. Saura C, Sánchez O, Martínez S, Domínguez C, Dienstmann R, Ruíz-Pace F, Céspedes MC, Peñuelas Á, Cortés J, Llurba E, Córdoba O. Cancers (Basel) 2021;13(4):923.